Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
20mg Qd for 12 months
40-80mg Qd for 6 months
0.5g Bid for 6 months
Evolocumab 140mg subcutaneously injected, twice each month
General Hospital of ShenYang Military Region
Shenyang, China
RECRUITINGChanges in remodeling index after the statin treatment
remodeling index: crimed vessel area/normal vessel area on high-resolution MRI
Time frame: baseline, 6 months, 12 months after treatment
Changes in plaque burden after the statin treatment
plaque burden: crimed vessel wall area/crimed vessel area on high-resolution MRI
Time frame: baseline, 6 months, 12 months after treatment
Changes plaque composition in after the statin treatment
plaque composition: lipid core and fiber tissue of plaque on high-resolution MRI
Time frame: baseline, 6 months, 12 months after treatment
level of serum bio-markers compared with baseline
Serum level of LDL、hs-CRP、sLOX1 and oxLDL
Time frame: 6 months
level of serum bio-markers compared with baseline
Serum level of LDL、hs-CRP、sLOX1 and oxLDL
Time frame: 12 months
mRS (0-2)
proportion of mRS (0-2)
Time frame: 6 months
mRS (0-2)
proportion of mRS (0-2)
Time frame: 12 months
vascular events
incidence of Transient ischemic attack, stroke or other vascular events
Time frame: 6 months
vascular events
incidence of Transient ischemic attack, stroke or other vascular events
Time frame: 12 months
abnormal test data
incidence of abnormal liver function or muscle enzyme levels
Time frame: 12 months
any adverse event
incidence of adverse event
Time frame: 12 months
death of any causes
proportion of death
Time frame: 12months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.